Infections After Liver Transplantation

Transplantation of the Liver

Volumn , Issue , 2005, Pages 963-994

  Holt, Curtis D ^a,b   Winston, Drew J ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33847642699     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0118-2.50069-0     Document Type: Chapter

References (325)

1. S Kusne, JS Dummer, N Singh, et al. (1988) Infections after liver transplantation: An analysis of 101 consecutive cases. Medicine (Baltimore) 67 132-143.
2. JO Colonna, DJ Winston, JE Brill, et al. (1988) Infectious complications in liver transplantation. Arch Surg 23 360-364.
3. NL Ascher, PG Stock, GL Bumgardner, et al. (1988) Infection and rejection of primary hepatic transplant in 93 consecutive patients treated with triple immunosuppressive therapy. Surg Gynecol Obstet 167 474-484.
4. CV Paya, PE Hermans, JA Washington, et al. (1989) Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clin Proc 64 555-564.
5. DJ Winston, C Emmanouilides and RW Busuttil (1995) Infection in liver transplant recipients. Clin Infect Dis 21 2077-2091.
6. RB Freeman, RH Wiesner, JP Roberts, et al. (2004) Improving liver allocation: MELD and PELD. Am J Transplant 9(Suppl), 114-131.
7. JA Fishman and RH Rubin (1998) Infection in organ-transplant recipients. N Engl J Med 338 1741-1751.
8. N Singh and DL Patterson (1998) Mycobacterium tuberculosis infection in solid-organ transplant recipients: Impact and implications for management. Clin Infect Dis 27 1266-1277.
9. J Torre-Cisneros, JJ Caston, J Moreno, et al. (2004) Tuberculosis in the transplant candidate: Importance of early diagnosis and treatment. Transplantation 77 1376-1380.
10. SD Halpern, PA Ubel and AL Caplan (2002) Solid organ transplantation in HIV-infected patients. N Engl J Med 347 284.
11. JA Fishman (2003) Transplantation of patients intected with human immunodeficiency virus: No longer experimental but not yet routine. J Infect Dis 188 1405.
12. ME Roland and PG Stock (2003) Review of solid organ transplantation in HIV-infected patients. Transplantation 75 425.
13. M Green and S Webber (2003) Posttransplantation lymphoproliferative disorders. Pediatr Clin North Am 50 1471-1491.
14. RJ Orentas, DW Schauer Jr, FW Ellis, et al. (2003) Monitoring and modulation of Epstein-Barr virus loads in pediatric transplant patients. Pediatr Transplant 7 305-314.
15. PS Randhawa, RS Markin, TE Starzl and AJ Demetris (1990) Epstein-Barr virus–associated syndromes in immunosuppressed liver trans plant recipients: Clinical profile and recognition on routine allograft biopsy. Am J Surg Pathol 14 538-547.
16. KT Montone, H Friedman, RL Hodinka, et al. (1992) In situ hybridization for Epstein-Barr virus Notl repeats in posttransplant lymphoproliferative disorder. Mod Pathol 5 292-302.
17. MR Lucey, DM Graham, P Martin, et al. (1992) Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut 33 1390-1396.
18. AJ Demetris, R Jaffe and DG Sheahan (1986) Recurrent hepatitis B in liver allograft recipients. Am J Pathol 125 161-172.
19. P Lykavieris, M Fabre, J Yvart and F Alvarez (1993) HBV infection in pediatric liver transplantation. J Pediatr Gastroenterol Nutr 16 321-327.
20. C Feray, AL Zignego, D Samuel, et al. (1990) Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection: The liver transplantation model. Transplantation 49 1155-1158.
21. S Todo, AJ Demetris, D Van Thiel, et al. (1991) Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 13 619-626.
22. D Samuel, R Muller, G Alexander, et al. (1993) Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329 1842-1847.
23. P Rimoldi, LS Belli, GF Rondinara, et al. (1993) Recurrent HBV/HDV infections under different immunoprophylaxis protocols. Transplant Proc 25 2675-2676.
24. LD Ferrell, TL Wright, J Roberts, et al. (1992) Hepatitis C viral infection in liver transplant recipients. Hepatology 16 865-876.
25. TL Wright (1993) Liver transplantation for chronic hepatitis C viral infection. Gastroenterol Clin North Am 22 231-242.
26. EJ Gane, BC Portmann, NV Naoumov, et al. (1996) Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 334 815-820.
27. DM Anselmo, RM Ghobrial, LC Jung, et al. (2002) New era of liver transplantation for hepatitis B: A 17-year single-center experience. Ann Surg 235 611-619.
28. SH Han, J Ofman, C Holt, et al. (2000) An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 6 741-748.
29. RM Ghobrial (2003) Treatment for recurrent hepatitis C. Minerva Chir 58 693-703.
30. NA Terrault (2003) Prophylactic and preemptive therapies for hepatitis C virus–infected patients undergoing liver transplantation. Liver Transpl 9 S95-S100.
31. HR Rosen (2002) Hepatitis C in the liver transplant recipient: Current understanding and treatment. Microbes Infect 4 1253-1258.
32. S Saab, AJ Chang, S Comulada, et al. (2003) Outcomes of hepatitis C–and hepatitis B core antibody–positive grafts in orthotopic liver transplantation. Liver Transpl 9 1053-1061.
33. CV Paya, PE Hermans, RH Wiesner, et al. (1989) Cytomegalovirus hepatitis in liver transplantation: Prospective analysis of 93 consecutive orthotopic liver transplantations. J Infect Dis 160 752-758.
34. LH Sayage, TA Gonwa, RM Goldstein, et al. (1989) Cytomegalovirus infection in orthotopic liver transplantation. Transpl Int 2 96-101.
35. RH Rubin (2002) The direct and indirect effects of infection in liver transplantation: Pathogenesis, impact, and clinical management. Curr Clin Top Infect Dis 22 125-154.
36. N Singh (1998) Infectious diseases in the liver transplant recipient. Semin Gastrointest Dis 9 136-146.
37. SS Kanj, AI Sharara, PA Clavien and JD Hamilton (1996) Cytomegalovirus infection following liver transplantation: Review of the literature. Clin Infect Dis 22 537-549.
38. R Patel and CV Paya (1997) Infections in solid-organ transplant recipients. Clin Microbiol Rev 10 86-124.
39. R Patel, DR Snydman, RH Rubin, et al. (1996) Cytomegalovirus prophy laxis in solid organ transplant recipients. Transplantation 61 1279-1289.
40. RA Vilchez, J Fung and S Kusne (2002) Cryptococcosis in organ transplant recipients: An overview. Am J Transplant 2 575-580.
41. JE Blair and JL Logan (2001) Coccidioidomycosis in solid organ transplantation. Clin Infect Dis 33 1536-1544.
42. R Vinayek, V Balan, A Pinna, et al. (1998) Disseminated histoplasmosis in a patient after orthotopic liver transplantation. Clin Transplant 12 274-277.
43. N Singh, S Husain, M De Vera, et al. (2004) Cryptococcus neoformans infection in patients with cirrhosis, including liver transplant candidates. Medicine (Baltimore) 83 188-192.
44. M Angelis, JT Cooper and RB Freeman (2003) Impact of donor infections on outcome of orthotopic liver transplantation. Liver Transpl 9 451-462.
45. PL Hibbard and RH Rubin (1994) Clinical aspects of fungal infections in organ transplant recipients. Clin Infect Dis 19(Suppl 1), S33.
46. S Hadley and AW Karchmer (1995) Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am 9 1045.
47. N Singh (2009) Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am 17 1.
48. JA Hagerty, J Ortiz, D Reich and C Manzarbeitia (2003) Fungal infections in solid organ transplant patients. Surg Infect 4 263-271.
49. JA Fishman (2001) Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 33 1397-1405.
50. BM Kubak, DA Pegues, CD Holt, et al. (2000) Changing patterns of fungal infection in transplantation. Curr Opin Organ Transplant 5 176.
51. TJ Walsh and AH Groll (1999) Emerging fungal pathogens: Evolving challenges to immunocompromised patients for the twenty first century. Transpl Infect Dis 1 247.
52. Canadian Multicenter Transplant Study Group (1983) A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 309 809-815.
53. European FK506 Multicenter Study Group (1994) Randomised trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 344 423-428.
54. N Singh, T Gayowski, MM Wagener, et al. (1997) Invasive fungal infections in liver transplant recipients receiving tacrolimus as the primary immunosuppressive agent. Clin Infect Dis 24 179-184.
55. N Singh, T Gayowski, M Wagener, et al. (1996) Pulmonary infections in liver transplant recipients receiving tacrolimus. Changing pattern of microbial etiologies. Transplantation 61 396-401.
56. D Rifkind, T Marchioro, T Schneck and RB Hill Jr (1967) Systemic fungal infection complicating renal transplantation and immunosuppression therapy. Am J Med 43 28-38.
57. RJ Stratta (1993) Clinical patterns of cytomegalovirus infection after solid-organ transplantation. Transplant Proc 25 15-21.
58. RH Wiesner, E Marin, MK Porayko, et al. (1993) Advances in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation. Gastroenterol Clin North Am 22 351-366.
59. DL Paterson, N Singh, A Panebianco, et al. (1998) Infectious complications occurring in liver transplant recipients receiving mycophe nolate mofetil. Transplantation 66 593-598.
60. PK Peterson, HH Balfour, DS Fryd, et al. (1983) Risk factors in the development of cytomegalovirus-related pneumonia in renal transplant recipients. J Infect Dis 148 1121.
61. HR Rosen, CR Shackleton, L Higa, et al. (1997) Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 92 1453-1457.
62. JD Eason, J Blazek, A Mason, et al. (2001) Steroid-free immunosuppression through thymoglobulin induction in liver transplantation. Transplant Proc 33 1470-1471.
63. DR Nelson, C Soldevila-Pico, A Reed, et al. (2001) Anti–interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 7 1064-1070.
64. Y Calmus, JR Scheele, I Gonzalez-Pinto, et al. (2002) Immunoprophylaxis with basiliximab, a chimeric anti–interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 8 123-131.
65. TG Heffron, GA Smallwood, T Pillen, et al. (2002) Liver transplant induction trial of daclizumab to spare calcineurin inhibition. Transplant Proc 34 1514.
66. GR Ingle, TM Sievers and CD Holt (2000) Sirolimus: Continuing the evolution of transplant immunosuppression. Ann Pharmacother 34 1044-1055.
67. CG Groth, L Backman, JM Morales, et al. (1999) Sirolimus based therapy in human renal transplantation; similar efficacy and different toxicity compared with cyclosporine. Transplantation 67 1036-1042.
68. A Fisher, JM Seguel, AN de la Torre, et al. (2004) Effect of sirolimus on infection incidence in liver transplant recipients. Liver Transpl 10 193-198.
69. S Husain and N Singh (2002) The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis 35 53-61.
70. DL George, PM Arnow, AS Fox, et al. (1991) Bacterial infection as a complication of liver transplantation: Epidemiology and risk factors. Rev Infect Dis 13 387-396.
71. L Barkholt, BG Ericzon, J Tollemar, et al. (1993) Infections in human liver recipients: Different patterns early and late after transplantation. Transpl Int 6 77-84.
72. MM Wagener and VL Yu (1992) Bacteremia in transplant recipients: A prospective study of demographics, etiologic agents, risk factors, and outcomes. Am J Infect Control 20 239-247.
73. C Lumbreras, M Lizasoain, E Moreno, et al. (1992) Major bacterial infections following liver transplantation: A prospective study. Hepatogastroenterology 39 362-365.
74. N Singh, DL Patterson, T Gayowski, et al. (2000) Predicting bacteremia and bacteremic mortality in liver transplant patients. Liver Transpl 6 54-61.
75. N Singh, T Gayowski, MM Wagener, et al. (1997) Bloodstream infections in liver transplant recipients receiving tacrolimus. Clin Transplant 11 275-281.
76. N Singh, T Gayowski, MM Wagener, et al. (1997) Predictors and outcome of early versus late-onset major bacterial infections in liver transplant recipients receiving tacrolimus (FK506) as primary immunosuppression. Eur J Clin Microbiol Infect Dis 16 821-826.
77. A Said, N Safdar, MR Lucey, et al. (2004) Infected bilomas in liver transplant recipients, incidence, risk factors and implications for prevention. Am J Transplant 4 574-582.
78. D Desai, N Desai, P Nightingale, et al. (2003) Carriage of methicillin-resistant Staphylococcus aureus is associated with an increased risk of infection after liver transplantation. Liver Transpl 9 754-759.
79. J Torre-Cisneros, C Herrero, E Canas, et al. (2002) High mortality related with Staphylococcus aureus bacteremia after liver transplantation. Eur J Clin Microbiol Infect Dis 21 385-388.
80. EA Hagen, E Lautenbach, K Olthoff and EA Blumberg (2003) Low prevalence of colonization with vancomycin-resistant Enterococcus in patients awaiting liver transplantation. Am J Transplant 3 902-905.
81. M Bakir, JL Bova, KA Newell, et al. (2001) Epidemiology and clinical consequences of vancomycin-resistant enterococci in liver transplant patients. Transplantation 72 1032-1037.
82. SL Orloff, AM Busch, AJ Olyaei, et al. (1999) Vancomycin-resistant Enterococcus in liver transplant patients. Am J Surg 177 418-422.
83. BK Kubak and CD Holt (1999) Bacterial infections in the transplant patients. Ochsner Clin Rep 11 1-15.
84. DL Paterson, JD Rihs, C Squier, et al. (2003) Lack of efficacy of mupirocin in the prevention of infections with Staphylococcus aureus in liver transplant recipients and candidates. Transplantation 75 194-198.
85. F Bert, J Clarissou, F Durand, et al. (2003) Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients. J Clin Microbiol 4 5147-5152.
86. GA Papanicolaou, BR Meyers, J Meyers, et al. (1996) Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: Risk factors for acquisition and mortality. Clin Infect Dis 23 760-766.
87. AD Luber, RA Jacobs, M Jordan, et al. (1996) Relative importance of oral versus intravenous vancomycin exposure in the development of vancomycin-resistant enterococci. J Infect Dis 173 1292-1294.
88. MB Edmond, JF Ober, JD Dawson, et al. (1996) Vancomycin-resistant enterococcal bacteremia: Natural history and attributable mortality. Clin Infect Dis 23 1234-1239.
89. DJ Winston, C Emmanouilides, A Kroeber, et al. (2000) Quinupristin/dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 30 790-797.
90. U Odakowska-Jedynak, L Paczek, M Krawczyk, et al. (2003) Resistance of gram-positive pathogens to antibiotics is a therapeutic challenge after liver transplantation: Clinical experience in one center with linezolid. Transplant Proc 35 2304-2306.
91. CA Kauffman (2003) Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J Antimicrob Chemother 51(Suppl 3), 23-30.
92. EF Gouvea, RC Branco, RC Monteiro, et al. (2004) Outcome of infections caused by multiple drug-resistant bacteria in liver transplant recipients. Transplant Proc 36 958-960.
93. DL Paterson, N Singh, JD Rihs, et al. (2001) Control of an outbreak of infection due to extended-spectrum beta-lactamase–producing Escherichia coli in a liver transplantation unit. Clin Infect Dis 33 126-128.
94. N Singh, MM Wagener, A Obman, et al. (2004) Bacteremias in liver transplant recipients: Shift toward gram-negative bacteria as predominant pathogens. Liver Transpl 10 844-849.
95. N Singh, T Gayowski, JD Rihs, et al. (2001) Evolving trends in multiple-antibiotic–resistant bacteria in liver transplant recipients: A longitudinal study of antimicrobial susceptibility patterns. Liver Transpl 7 22-26.
96. J Wade, N Rolando and R Williams (1998) The significance of aerobic gram-negative bacilli in clinical specimens following orthotopic liver transplantation. Liver Transpl Surg 4 51-57.
97. NM Clark and CE Chenoweth (2003) Aeromonas infection of the hepatobiliary system: Report of 15 cases and review of the literature. Clin Infect Dis 37 506-513.
98. P Lykavieris, M Fabre, D Pariente, et al. (2003) Clostridium difficile colitis associated with inflammatory pseudotumor in a liver transplant recipient. Pediatr Transplant 7 76-79.
99. K Keven, A Basu, L Re, et al. (2004) Clostridium difficile colitis in patients after kidney and pancreas-kidney transplantation. Transpl Infect Dis 6 10-14.
100. P Munoz, J Palomo, J Yanez and E Bouza (2001) Clinical microbiological case: A heart transplant recipient with diarrhea and abdominal pain. Recurring C. difficile infection. Clin Microbiol Infect 7 451-452. 458–459
101. JG Bartlett (2002) Antibiotic-associated diarrhea. N Engl J Med 346 334-339.
102. GM Forbes, FA Harvey, JN Philpott-Howard, et al. (1990) Nocardiosis in liver transplantation: Variation in presentation, diagnosis and therapy. J Infect 20 11-19.
103. M Weinberger, A Eid, L Schreiber, et al. (1995) Disseminated Nocardia transvalensis infection resembling pulmonary infarction in a liver transplant recipient. Eur J Clin Microbiol Infect Dis 14 337-341.
104. NM Ampel and EJ Wing (1990) Legionella infection in transplant patients. Semin Respir Infect 5 30-37.
105. A Ernst, FD Gordon, J Hayek, et al. (1998) Lung abscess complicating Legionella micdadei pneumonia in an adult liver transplant recipient: Case report and review. Transplantation 65 130-134.
106. P Seu, DJ Winson, KM Olthoff, et al. (1993) Legionnaires' disease in liver transplant recipients. Infect Dis Clin Pract 2 109-113.
107. Y Tokunaga, W Conception, WE Berquist, et al. (1992) Graft involvement by Legionella in a liver transplant recipient. Arch Surg 127 475-477.
108. CA Rettally and KV Speeg (2003) Infection with Listeria monocytogenes following orthotopic liver transplantation: Case report and review of the literature. Transplant Proc 35 1485-1487.
109. C Lumbreras, M Lizasoain, E Moreno, et al. (1992) Major bacterial infections following liver transplantation: A prospective study. Hepatogastroenterology 39 362-365.
110. PM Arnow (1991) Infections following orthotopic liver transplantation. HPB Surg 3 221-233.
111. KL Brayman, E Stephanian, AJ Matas, et al. (1992) Analysis of infectious complications occurring after solid-organ transplantation. Arch Surg 127 38-48.
112. ME Bubak, MK Porayko, RA Krom and RH Wiesner (1991) Complications of liver biopsy in liver transplant patients: Increased sepsis associated with choledochojejunostomy. Hepatology 14 1063-1065.
113. A Pirat, S Ozgur, A Torgay, et al. (2004) Risk factors for postoperative respiratory complications in adult liver transplant recipients. Transplant Proc 36 218-220.
114. LA Mennel and D Maki (1990) Bacterial pneumonia in solid organ transplantation. Semin Respir Infect 5 10-29.
115. RS Markin, RJ Stratta and GL Woods (1990) Infection after liver transplantation. Am J Surg Pathol 14(Suppl 1), 64-78.
116. J Philpott-Howard, A Burroughs, N Fisher, et al. (2003) Piperacillin-tazobactam versus ciprofloxacin plus amoxicillin in the treatment of infective episodes after liver transplantation. J Antimicrob Chemother 52 993-1000.
117. JJ Fung (2002) Fungal infection in liver transplantation. Transpl Infect Dis 4(Suppl 3), 18-23.
118. JA Fishman (2002) Overview: Fungal infections in the transplant patients. Transpl Infect Dis 4(Suppl 3), 3.
119. N Singh, NM Wagener and T Gayowski (2002) Trends in invasive fungal infections in liver transplant recipients: Correlation with evolution in transplant practices. Transplantation 73 63-67.
120. P Castaldo, RJ Stratta, RP Wood, et al. (1991) Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg 126 149-156.
121. CV Paya (1993) Fungal infections in solid-organ transplantation. Clin Infect Dis 16 677-688.
122. JM Rabkin, SL Oroloff, CL Corless, et al. (2000) Association of fungal infection and increased mortality in liver transplant recipients. Am J Surg 179 426-430.
123. S Husain, J Tollemar, EA Dominguez, et al. (2003) Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: Prospective, multicenter, case-controlled study. Transplantation 75 2023-2029.
124. MA Viviani, AM Tortorano, C Malaspina, et al. (1992) Surveillance and treatment of liver transplant recipients for candidiasis and aspergillosis. Eur J Epidemiol 8 433-436.
125. R Patel, D Poertela, A Badley, et al. (1996) Risk factors of invasive candida and non-candida fungal infections after liver transplantation. Transplantation 62 926.
126. YH Samaranayake and LP Samaranayake (1994) Candida krusei: Biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen. J Med Microbiol 41 295.
127. J Fortun, A Lopez-San Roman, JJ Velasco, et al. (1997) Selection of Candida glabrata with reduced susceptibility to azoles in four liver transplant recipients with invasive candidiasis. Eur J Clin Microbiol Infect Dis 16 314.
128. JA Nieto-Rodriguez, S Kusne, R Manez, et al. (1996) Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. Ann Surg 223 70-76.
129. N Singh, PM Arnow, A Bonham, et al. (1997) Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 64 716.
130. RS Brown Jr, JR Lake, BA Katzman, et al. (1996) Incidence and significance of Aspergillus cultures following liver and kidney transplantation. Transplantation 61 666-669.
131. N Singh, RK Avery, P Munoz, et al. (2003) Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 36 46-52.
132. J Fortun, P Martin-Davila, S Moreno, et al. (2002) Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 8 1065-1070.
133. S Husain, BD Alexander, P Munoz, et al. (2003) Opportunistic mycelial fungal infections in organ transplant recipients: Emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 37 221-229.
134. S Husain, MN Wagener and N Singh (2001) Cryptococcus neoformans infection in organ transplant recipients: Variables influencing clinical characteristics and outcome. Emerg Infect Dis 7 375-381.
135. CD Holt, DJ Winston, BK Kubak, et al. (1997) Coccidioidomycosis in liver transplantation. Clin Infect Dis 24 216.
136. FK Welty, GX McLeod, C Ezratty, et al. (1992) Pseudallescheria boydii endocarditis of the pulmonic valve in a liver transplant recipient. Clin Infect Dis 15 858-860.
137. BD Alexander (2002) Diagnosis of fungal infection: New technologies for the mycology laboratory. Transpl Infect Dis 4(Suppl 3), 32-37.
138. TF Patterson (1999) Approaches to fungal diagnosis in transplantation. Transpl Infect Dis 1 262-272.
139. PE Verweij and JF Meis (2000) Microbiological diagnosis of invasive fungal infections in transplant recipients. Transpl Infect Dis 2 80.
140. T Walsh and PA Pizzo (1992) Laboratory diagnosis of candidiasis. GP Bodry (Eds) Candidiasis New York: Raven Press 109-135.
141. S Kusne, J Torre-Cisneros, R Manez, et al. (1992) Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation. J Infect Dis 166 1379-1383.
142. JJ Wheat (2003) Rapid diagnosis of invasive aspergillosis by antigen detection. Transpl Infect Dis 5 158-166.
143. EJ Kwak, S Husain, A Obman, et al. (2004) Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol 42 435-438.
144. NJ Mueller and JA Fishman (2003) Asymptomatic pulmonary cryptococcosis in solid organ transplantation: Report of four cases and review of the literature. Transpl Infect Dis 5 140-143.
145. N Singh, T Gayowski, MM Wagener, et al. (1997) Clinical spectrum of invasive cryptococcosis in liver transplant recipients receiving tacrolimus. Clin Transplant 11 66-70.
146. G Wu, RA Vilchez, B Eidelman, et al. (2002) Cryptococcal meningitis: An analysis among 5,521 consecutive organ transplant recipients. Transpl Infect Dis 4 183-188.
147. N Singh, T Gayowski, J Singh and VL Yu (1995) Invasive gastrointestinal zygomycosis in a liver transplant recipient: Case report and review of zygomycosis in solid-organ transplant recipients. Clin Infect Dis 20 617-620.
148. B Castiglioni, DA Sutton, MG Rinaldi, et al. (2002) Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine (Baltimore) 81 333-348.
149. EM Baily, DJ Krakovsky and M Rybak (1990) The triazole antifungal agents: A review of itraconazole and fluconazole. Pharmacotherapy 10 146.
150. A Wong-Beringer and J Kriengkauykiat (2003) Systemic antifungal therapy: New options, new challenges. Pharmacotherapy 23 1441.
151. GP Bodey (1992) Azole antifungal agents. J Infect Dis 14(Suppl 1), S161-S169.
152. C Lumbreras, V Cuervas-Mons, P Jara, et al. (1996) Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 174 583.
153. DJ Winston, A Pakrasi and RW Busuttil (1999) Fluconazole prophylaxis of fungal infections in liver transplant recipients: Results of a placebo-controlled, double blind trial. Ann Intern Med 131 729.
154. R Patel (2000) Prophylactic fluconazole in liver transplant recipients: A randomized, double-blind, placebo-controlled trial. Liver Transpl 6 376.
155. DJ Winston and RW Busuttil (2002) Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 74 688.
156. MD Sharpe, C Ghent, D Grant, et al. (2003) Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: A prospective, randomized, double-blind study. Transplantation 76 977.
157. J Tollemar, K Hockerstedt, BG Ericzon, et al. (1995) Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. Transplantation 59 45.
158. MM Pearson, PD Rogers, JD Cleary, et al. (2003) Voriconazole: A new triazole antifungal agent. Ann Pharmacother 37 420.
159. E Albengres, H Lelouet and JP Tillement (1998) Systemic antifungal agents: Drug interactions of clinical significance. Drug Saf 18 83.
160. G Mignat (1997) Clinically significant drug interactions with new immunosuppressive agents. Drug Saf 16 267.
161. U Christians, W Jacobson, LZ Benet, et al. (2002) Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 41 813.
162. C Campana, MB Regazzi, I Buggia, et al. (1996) Clinically significant drug interactions with cyclosporine. Clin Pharmacokinet 30 141.
163. Voriconazole (prescribing information).
164. DW Denning (2003) Echinocandin antifungal drugs. Lancet 362 1142.
165. MD Johnson and JR Perfect (2003) Caspofungin: First approved agent in a new class of antifungals. Exp Opin Pharmacother 4 807.
166. Caspofungin (prescribing information).
167. HA Gallis, RH Drew and WW Pickard (1990) Amphotericin B: 30 years of clinical experience. Rev Infect Dis 12 308.
168. A Kucers, S Crowe, ML Grayson and J Hoy (1997) The Use of Antibiotics 5th ed. Butterworth-Heinemann 1245-1294.
169. R Herbrecht, S Natarajan-Ame, Y Nivoix, et al. (2003) The lipid formulations of amphotericin B. Exp Opin Pharmacother 4 1277.
170. A Wong-Beringer, RA Jacobs and BJ Guglielmo (1998) Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin Infect Dis 27 603.
171. R Janknegt, S DeMarie, AJM Bakker-Woudenberg and JA Crommelin (1992) Liposomal and lipid formulations of amphotericin B. Drugs 23 279.
172. S Singhal, RW Ellis, SG Jones, et al. (2000) Targeted prophylaxis with amphotericin B lipid complex in liver transplantation. Liver Transpl 6 588-595.
173. N Singh, DL Patterson, T Gayowski, et al. (2001) Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 71 910-913.
174. NC Fisher, S Singhal, SJ Miller, et al. (1999) Fungal infection and liposomal amphotericin B (AmBisome) therapy in liver transplantation: A 2 year review. J Antimicrob Chemother 43 597-600.
175. P Linden, P Williams and KM Chan (2000) Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clin Transplant 14(4 Pt 1), 329-339.
176. T Lorf, D Braun, R Ruchel, et al. (1999) Systemic mycoses during prophylactical use of liposomal amphotericin B (Ambisome) after liver transplantation. Mycoses 42 47-53.
177. J Fortun, P Martin-Davila, S Moreno, et al. (2003) Prevention of invasive fungal infections in liver transplant recipients: The role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 52 813.
178. R Herbrecht, DW Denning, TF Patterson, et al. (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 408-415.
179. S Tsiodras, R Zafiropoulou, J Giotakis, et al. (2004) Deep sinus aspergillosis in a liver transplant recipient successfully treated with a combination of caspofungin and voriconazole. Transpl Infect Dis 6 37-40.
180. W van der Bij and R Speich (2001) Management of cytomegalovirus infection and disease after solid-organ transplantation. Clin Infect Dis 33(Suppl 1), S32-S37.
181. CV Paya (2001) Prevention of cytomegalovirus disease in recipients of solid-organ transplants. Clin Infect Dis 32 596-603.
182. PL Hibberd and DR Snydman (1995) Cytomegalovirus infection in organ transplant recipients. Infect Dis Clin North Am 9 863-877.
183. N Singh, C Wannstedt, L Keyes, et al. (2004) Impact of evolving trends in recipient and donor characteristics on cytomegalovirus infection in liver transplant recipients. Transplantation 77 106-110.
184. S Singhal, OA Khan, RA Bramble, et al. (2003) Cytomegalovirus disease following liver transplantation: An analysis of prophylaxis strategies. J Infect 47 104-109.
185. S Kusne, R Shapiro and J Fung (1999) Prevention and treatment of cytomegalovirus infection in organ transplant recipients. Transpl Infect Dis 1 187-203.
186. RJ Stratta, MS Shaefer, RS Markin, et al. (1989) Clinical patterns of cytomegalovirus disease after liver transplantation. Arch Surg 124 1443-1450.
187. N Singh, JS Dummer, S Kusne, et al. (1988) Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: Transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 158 124-131.
188. B Sido, WJ Hoffman, G Otto, et al. (1993) Cytomegalovirus infection of the liver graft early after transplantation: Incidence and clinical relevance. Transplant Proc 25 2671-2672.
189. O Bronsther, L Makowka, R Jaffe, et al. (1988) Occurrence of cytomegalovirus hepatitis in liver transplant patients. J Med Virol 24 423-434.
190. M Alessiani, S Kusne, JJ Fung, et al. (1991) CMV infection in liver transplantation under cyclosporine or FK506 immunosuppression. Transplant Proc 23 3035-3037.
191. JG O'Grady, GJ Alexander, S Sutherland, et al. (1988) Cytomegalovirus infection and donor/recipient HLA antigens: Interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet 2 302-305.
192. CV Paya, RH Wiesner, PE Hermans, et al. (1992) Lack of association between cytomegalovirus infection, HLA matching and the vanishing bile duct syndrome after liver transplantation. Hepatology 16 66-70.
193. P Pancholi, F Wu and P Della-Latta (2004) Rapid detection of cytomegalovirus infection in transplant patients. Exp Rev Mol Diagn 4 231-242.
194. R Schroeder, T Michelon, I Fagundes, et al. (2004) Comparison between RFLP-PCR and antigenemia for pp65 antigen for diagnosis of cytomegalovirus disease after kidney transplantation. Transplant Proc 36 891-893.
195. MM Abecassis, AJ Koffron, B Kaplan, et al. (1997) The role of PCR in the diagnosis and management of CMV in solid organ recipients: What is the predictive value for the development of disease and should PCR be used to guide antiviral therapy? Transplantation 63 275-279.
196. CV Paya, TF Smith and J Ludwig (1989) Rapid shell vial culture and tissue histology compared with serology for the rapid diagnosis of cytomegalovirus infection in liver transplantation. Mayo Clin Proc 64 670-675.
197. S Norris, Y Kosar and N Donaldson (2002) Cytomegalovirus infection after liver transplantation: Viral load as a guide to treating clinical infection. Transplantation 74 527-531.
198. H Piiparinen, K Hockerstedt, C Gronhagen-Riska, et al. (2001) Comparison of plasma polymerase chain reaction and pp65-antigenemia assay in the quantification of cytomegalovirus in liver and kidney transplant patients. J Clin Virol 22 111-116.
199. F Pereyra and RH Rubin (2004) Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 17 357-361.
200. JK McGavin and KL Goa (2001) Ganciclovir: An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 61 1153-1183.
201. JC Scott, N Partovi and MH Ensom (2004) Ganciclovir in solid organ transplant recipients: Is there a role for clinical pharmacokinetic monitoring? Ther Drug Monit 26 68-77.
202. DR Snydman (2001) Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation. Transpl Infect Dis 3(Suppl 2), 6-13.
203. E Mylonakis, WM Kallas, JA Fishman, et al. (2002) Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis 34 1337-1341.
204. CM Isada, B Yen-Lieberman, NS Lurain, et al. (2002) Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Transpl Infect Dis 4 189-194.
205. AP Limaye (2002) Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 35 866-872.
206. IG Sia and R Patel (2000) New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 13 83-121.
207. RJ Stratta, MS Shaefer, KA Cushing, et al. (1991) Successful prophylaxis of cytomegalovirus disease after primary CMV exposure in liver transplant recipients. Transplantation 51 90-97.
208. F Saliba, D Eyraud, D Samuel, et al. (1993) Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients. Transplant Proc 25 1444-1445.
209. N Singh, VL Yu, L Mieles, et al. (1994) High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients: A randomized trial. Ann Intern Med 120 375-381.
210. DR Snydman, BG Werner, NN Dougherty, et al. (1993) Cytomegalovirus immune globulin prophylaxis in liver transplantation: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 119 984-991.
211. M Martin, R Manez, P Linden, et al. (1994) A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 58 779-785.
212. DJ Winston, D Wirin, A Shaked and RW Busuttil (1995) Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 346 69-74.
213. M Green, M Kaufmann, J Wilson and J Reyes (1997) Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis 25 1344-1349.
214. SM King, R Superina, W Andrews, et al. (1997) Randomized comparison of ganciclovir plus intravenous immune globulin (IVIG) with IVIG alone for prevention of primary cytomegalovirus disease in children receiving liver transplants. Clin Infect Dis 25 1173-1179.
215. J Gavalda, J de Otero, E Murio, et al. (1997) Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients. Transpl Int 10 462-465.
216. E Gane, F Saliba, GJ Valdecasas, et al. (1997) Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet 350 1729-1733.
217. AD Badley, EC Seaberg, MK Porayko, et al. (1997) Prophylaxis of cytomegalovirus infection in liver transplantation: A randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database. Transplantation 64 66-73.
218. DJ Winston and RW Busuttil (2003) Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Transplantation 75 229-233.
219. DJ Winston and RW Busuttil (2004) Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors. Transplantation 77 305-308.
220. MD Pescovitz, J Rabkin, RM Merion, et al. (2000) Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 44 2811-2815.
221. C Paya, A Humar, E Dominguez, et al. (2004) Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4 611-620.
222. G Boivin, N Goyette, C Gilbert, et al. (2004) Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 189 1615-1618.
223. E Akalin, V Sehgal, S Ames, et al. (2003) Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 3 731-735.
224. MD Pescovitz (2003) Formulary considerations for drugs used to prevent cytomegalovirus disease. Am J Health Syst Pharm 60(23 Suppl 8), S17-S21.
225. KT Sommerville (2003) Cost advantages of oral drug therapy for managing cytomegalovirus disease. Am J Health Syst Pharm 60(23 Suppl 8), S9-S12.
226. A Das (2003) Cytomegalovirus infection in solid organ transplantation: Economic implications. Pharmacoeconomics 21 467-475.
227. JS Daly, A Kopasz, R Anandakrishnan, et al. (2002) Preemptive strategy for ganciclovir administration against cytomegalovirus in liver transplantation recipients. Am J Transplant 2 955-958.
228. CV Paya, JA Wilson, MJ Espy, et al. (2002) Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: A randomized, placebo-controlled trial. J Infect Dis 185 854-860.
229. J Torre-Cisneros, JA Madueno, C Herrero, et al. (2002) Pre-emptive oral ganciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients. Clin Microbiol Infect 8 773-780.
230. N Singh, DL Paterson, T Gayowski, et al. (2000) Cytomegalovirus anti-genemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: A randomized, controlled trial. Transplantation 70 717-722.
231. N Raves, D Seehofer, CA Schmidt, et al. (2001) Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation. Transplantation 72 881-885.
232. P Seu, DJ Winston, CD Holt, et al. (1997) Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors. Transplantation 64 1614-1617.
233. T Yoshikawa (2003) Significance of human herpesviruses to transplant recipients. Curr Opin Infect Dis 16 601-606.
234. P Ljungman (2001) Prophylaxis against herpesvirus infections in transplant recipients. Drugs 61 187-196.
235. EB Haagsma, U Klompmaker, J Grond, et al. (1987) Herpes virus infections after orthotopic liver transplantation. Transplant Proc 19 4054-4056.
236. S Gourishankar, JC McDermid, GS Jhangri and JK Preiksaitis (2004) Herpes zoster infection following solid organ transplantation: Incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 4 108-115.
237. SJ Pacini-Edelstein, M Mehra, ME Ament, et al. (2003) Varicella in pediatric liver transplant patients: A retrospective analysis of treatment and outcome. J Pediatr Gastroenterol Nutr 37 183-186.
238. RD Holmes and RJ Sokol (2002) Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant 6 456-464.
239. C Duvoux, GP Pageaux, C Vanlemmens, et al. (2002) Risk factors for lymphoproliferative disorders after liver transplantation in adults: An analysis of 480 patients. Transplantation 74 1103-1109.
240. MD Fellner, K Durand, M Correa, et al. (2003) A semiquantitative PCR method (SQ-PCR) to measure Epstein-Barr virus (EBV) load: Its application in transplant patients. J Clin Virol 3 323-330.
241. A Jain, M Nalesnik, J Reyes, et al. (2002) Posttransplant lymphoproliferative disorders in liver transplantation: A 20-year experience. Ann Surg 236 429-436.
242. M Hurwitz, DM Desai, KL Cox, et al. (2004) Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation. Pediatr Transplant 8 267-272.
243. RR Razonable and CV Paya (2003) Herpesvirus infections in transplant recipients: Current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 10 60-65.
244. V Ganne, N Siddiqi, B Kamaplath, et al. (2003) Humanized anti-CD20 monoclonal antibody (rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant 17 417-422.
245. S Yedibela, T Reck, G Niedobitek, et al. (2003) Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation. Transpl Int 16 197-201.
246. RR Razonable and CV Paya (2002) The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation. Liver Transpl 8 651-658.
247. N Singh, S Husain, DR Carrigan, et al. (2002) Impact of human herpesvirus-6 on the frequency and severity of recurrent hepatitis C virus hepatitis in liver transplant recipients. Clin Transplant 16 92-96.
248. VC Emery (2001) Human herpesviruses 6 and 7 in solid organ transplant recipients. Clin Infect Dis 32 1357-1360.
249. N Singh (2000) Human herpesviruses-6, -7 and -8 in organ transplant recipients. Clin Microbiol Infect 6 453-459.
250. J Rogers, S Rohal, DR Carrigan, et al. (2000) Human herpesvirus-6 in liver transplant recipients: Role in pathogenesis of fungal infections, neurologic complications, and outcome. Transplantation 69 2566-2573.
251. AG Marcelin, AM Roque-Afonso, M Hurtova, et al. (2004) Fatal disseminated Kaposi's sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients. Liver Transpl 10 295-300.
252. A Garcia-Sesma, C Jimenez, C Loinaz, et al. (2003) Kaposi's visceral sarcoma in liver transplant recipients. Transplant Proc 35 1898-1899.
253. UD Allen (2002) Human herpesvirus type 8 infections among solid organ transplant recipients. Pediatr Transplant 6 187-192.
254. F Pozo, A Tenorio, M de la Mata, et al. (2000) Persistent human herpesvirus 8 viremia before Kaposi's sarcoma development in a liver transplant recipient. Transplantation 70 395-397.
255. F Colina, F Lopez-Rios, C Lumbreras, et al. (1996) Kaposi's sarcoma developing in a liver graft. Transplantation 61 1779-1781.
256. D McGrath, ME Falagas, R Freeman, et al. (1998) Adenovirus infection in adult orthotopic liver transplant recipients: Incidence and clinical significance. J Infect Dis 177 459-462.
257. RS Saad, AJ Demetris, RG Lee, et al. (1997) Adenovirus hepatitis in the adult allograft liver. Transplantation 64 1483-1485.
258. MG Michaels, M Green, ER Wald and TE Starzl (1992) Adenovirus infection in pediatric liver transplant recipients. J Infect Dis 165 170-174.
259. B Koneru, R Jaffe, CO Esquivel, et al. (1987) Adenoviral infections in pediatric liver transplant recipients. JAMA 258 489-492.
260. S Boubenider, C Hiesse, S Marchand, et al. (1999) Post-transplantation polyomavirus infections. J Nephrol 12 24-29.
261. E Mylonakis, N Goes, RH Rubin, et al. (2001) BK virus in solid organ transplant recipients: An emerging syndrome. Transplantation 72 1587-1592.
262. DJ Bronster, MW Lidov, D Wolfe, et al. (1995) Progressive multifocal leukoencephalopathy after orthotopic liver transplantation. Liver Transpl Surg 1 371-372.
263. RA Vilchez, K McCurry, J Dauber, et al. (2002) Influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2 287-291.
264. S Krinzman, N Basgoz, R Kradin, et al. (1998) Respiratory syncytial virus-associated infections in adult recipients of solid organ transplants. J Heart Lung Transplant 17 202-210.
265. S Singhal, DA Muir, DA Ratcliffe, et al. (1999) Respiratory viruses in adult liver transplant recipients. Transplantation 68 981-984.
266. C Pohl, M Green, ER Wald and J Ledesma-Medina (1992) Respiratory syncytial virus infections in pediatric liver transplant recipients. J Infect Dis 165 166-169.
267. OK Ndimbie, E Frezza, JA Jordan, et al. (1996) Parvovirus B19 in anemic liver transplant recipients. Clin Diagn Lab Immunol 3 756-760.
268. FY Chang, N Singh, T Gayowski and IR Marino (1996) Parvovirus B19 infection in a liver transplant recipient: Case report and review in organ transplant recipients. Clin Transplant 10 243-247.
269. JS Dummer, S Erb, MK Breinig, et al. (1989) Infection with human immunodeficiency virus in the Pittsburgh transplant population: A study of 583 donors and 1043 recipients, 1981–1986. Transplantation 47 134-140.
270. RJ Simonds, SD Holmberg, RL Hurwitz, et al. (1992) Transmission of human immunodeficiency virus type 1 from a seronegative organ and tissue donor. N Engl J Med 326 726-732.
271. ME Roland, D Adey, LL Carlson and NA Terrault (2003) Kidney and liver transplantation in HIV-infected patients: Case presentations and review. AIDS Patient Care STDs 17 501-507.
272. ME Roland, B Lo, J Braff and PG Stock (2003) Key clinical, ethical, and policy issues in the evaluation of the safety and effectiveness of solid organ transplantation in HIV-infected patients. Arch Intern Med 163 1773-1778.
273. PC Kuo and R Stock (2001) Transplantation in the HIV+ patient. Am J Transplant 1 13-17.
274. PJ Gow, D Pillay and D Mutimer (2001) Solid organ transplantation in patients with HIV infection. Transplantation 72 177-181.
275. SK Jacobson, RY Calne and TG Wreghitt (1991) Outcome of HIV infection in transplant patient on cyclosporin. Lancet 337 794.
276. D Samuel, JC Duclos Vallee, E Teicher and D Vittecoq (2003) Liver transplantation in patients with HIV infection. J Hepatol 39 3-6.
277. MJ Alter, D Kruszon-Moran, OV Nainan, et al. (1999) The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341 556-562.
278. SL Flamm (2003) Chronic hepatitis C infection. JAMA 289 2413-2417.
279. JB Wong, GM McQuillan, JG McHutchison and T Poynard (2000) Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 90 1562-1569.
280. M Berunguer (2002) Natural history of recurrent hepatitis C. Liver Transpl 8(Suppl 1), S14-S18.
281. M Charlton, E Seaberg, R Wiesner, et al. (1998) Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 28 823-830.
282. M Berenguer, L Ferrell, J Watson, et al. (2000) HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 32 673-684.
283. MW Johnson, WK Washburn, RB Freeman, et al. (1996) Hepatitis C viral infection in liver transplantation. Arch Surg 131 284-291.
284. M Berenguer, M Prieto, A Palau, et al. (2003) Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl 9 228-235.
285. LM Forman, JD Lewis, JA Berlin, et al. (2002) The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122 889-896.
286. K McLaughlin, S Wajsaub, P Marotta, et al. (2000) Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transpl 6 570-574.
287. GA Abrahamian, AB Cosimi, ML Farrell, et al. (2000) Prevalence of hepatitis C virus-associated mixed cryoglobulinemia after liver transplantation. Liver Transpl 6 185-190.
288. M Khalili, JW Lim, N Bass, et al. (2004) New onset diabetes mellitus after liver transplantation: The critical role of hepatitis C infection. Liver Transpl 10 349-355.
289. RM Ghobrial, R Steadman, J Gombein, et al. (2001) A 10-year experience of liver transplantation for hepatitis C: Analysis of factors determining outcome in over 500 patients. Ann Surg 234 384-393.
290. HR Rosen (2000) Retransplantation for hepatitis C: Implications of different policies. Liver Transpl 6(Suppl 2), S41-S46.
291. SJ Pelletier, DP Raymond, TD Crabtree, et al. (2000) Pretransplantation hepatitis C virus quasispecies may be predictive of outcome after liver transplantation. Hepatology 32 375-381.
292. V Dimartino, F Saurini, D Samuel, et al. (1997) Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation. Hepatology 26 1343-1350.
293. M Charlton (2003) The impact of advancing donor age on histologic recurrence of hepatitis C infection: The perils of ignored maternal advice. Liver Transpl 9 535-537.
294. PA Sheiner, ME Schwartz, E Mor, et al. (1995) Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 21 30-34.
295. M Berenguer, FX Lopez-Labrador, HB Greenberg, et al. (2000) Hepatitis C virus and the host: An imbalance induced by immunosuppression? Hepatology 32 433-435.
296. RH Wiesner (1998) A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: A report of the United States FK506 Study Group. Transplantation 66 493.
297. AR Mueller, K Platz, C Willimski, et al. (2001) Influence of immunosuppression on patient survival after liver transplantation for hepatitis C. Transplant Proc 33 1347-1349.
298. M Charlton and E Seaberg (1999) Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 5(Suppl 1), S107.
299. GV Papatheodoridis, S Davies, AP Dhillon, et al. (2001) The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. Transplantation 72 412.
300. A Jain, R Kashyap, AJ Demetris, et al. (2002) A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 8 40.
301. CG Fasola, GJ Netto, LL Christensen, et al. (2002) Delay of hepatitis C recurrence in liver transplant recipients: Impact of mycophenolate mofetil on transplant recipients with severe acute rejection or with renal dysfunction. Transplant Proc 34 1561.
302. GA Smallwood, L Davis, E Martinez, et al. (2002) Mycophenolate's influence in the treatment of recurrent hepatitis C following liver transplantation. Transplant Proc 34 1559.
303. P Neuhaus, PA Clavien, D Kittur, et al. (2002) Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: Results from a double-blind randomized placebocontrolled trial. Liver Transpl 8 132.
304. Y Calmus, JR Scheele, I Gonzalez-Pinto, et al. (2002) Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprinecontaining triple therapy in liver transplant recipients. Liver Transpl 8 123-131.
305. DR Nelson, C Soldevila-Pico, A Reed, et al. (2001) Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 7 1064-1070.
306. MJ Hayes, PJ Torzillo, AG Sheil, et al. (1994) Pneumocystis carinii pneumonia after liver transplantation in adults. Clin Transplant 8 499-503.
307. JL Colombo, PH Sammut, AN Langnas and BW Shaw (1992) The spectrum of Pneumocystis carinii infection after liver transplantation in children. Transplantation 54 621-624.
308. T Gluck, HF Geerdes-Fenge, RH Straub, et al. (2000) Pneumocystis carinii pneumonia as a complication of immunosuppressive therapy. Infection 28 227-230.
309. B Meyers, F Borrego, G Papanicolaou, et al. (2001) Pneumocystis carinii pneumonia prophylaxis with atovaquone in trimethoprim sulfamethoxazole-intolerant orthotopic liver transplant patients: A preliminary study. Liver Transpl 7 750-751.
310. J Torre-Cisneros, M de la Mata, P Lopez-Cillero, et al. (1996) Effectiveness of daily low-dose cotrimoxazole prophylaxis for Pneumocystis carinii pneumonia in liver transplantation—an open clinical trial. Transplantation 62 1519-1521.
311. K Saukkonen, R Garland and H Koziel (1996) Aerosolized pentamidine as alternative primary prophylaxis against Pneumocystis carinii pneumonia in adult hepatic and renal transplant recipients. Chest 109 1250-1255.
312. SM Gordon, SP LaRosa, S Kalmadi, et al. (1999) Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 28 240-246.
313. LA Barcan, ML Dallurzo, LO Clara, et al. (2002) Toxoplasma gondii pneumonia in liver transplantation: Survival after a severe case of reactivation. Transpl Infect Dis 4 93-96.
314. R Patel (1999) Disseminated toxoplasmosis after liver transplantation. Clin Infect Dis 29 705-706.
315. M Lappalainen, TS Jokiranta and L Halme (1998) Disseminated toxoplasmosis after liver transplantation: Case report and review. Clin Infect Dis 27 1327-1328.
316. A Salt, G Sutehall, M Sargaison, et al. (1990) Viral and Toxoplasma gondii infections in children after liver transplantation. J Clin Pathol 43 63-67.
317. TG Wreghitt (1987) Viral and Toxoplasma gondii infections. R Came (Eds) Liver Transplantation 2nd ed. London: Grune & Stratton 365-383.
318. S Kusne, JS Dummer, M Ho, et al. (1987) Self-limited Toxoplasma parasitemia after liver transplantation. Transplantation 44 457-458.
319. N Safdar, A Said and MR Lucey (2004) The role of selective digestive decontamination for reducing infection in patients undergoing liver transplantation: A systematic review and meta-analysis. Liver Transpl 10 817-827.
320. WC Hellinger, JD Yao, S Alvarez, et al. (2002) A randomized, prospective, double-blinded evaluation of selective bowel decontamination in liver transplantation. Transplantation 73 1904-1909.
321. PM Arnow, GC Carandang, R Zabner and ME Irwin (1996) Randomized controlled trial of selective bowel decontamination for prevention of infections following liver transplantation. Clin Infect Dis 22 997-1003.
322. PM Arnow (1995) Prevention of bacterial infection in the transplant recipient. The role of selective bowel decontamination. Infect Dis Clin North Am 9 849-862.
323. RH Wiesner, PE Hermans, J Rakela, et al. (1988) Selective bowel decontamination to decrease gram-negative aerobic bacterial and Candida colonization and prevent infection after orthotopic liver transplantation. Transplantation 45 570-574.
324. R Rossaint, R Raakow, K Lewandowski, et al. (1991) Strategy for prevention of infection after orthotopic liver transplantation. Transplant Proc 23 1965-1966.
325. MJ Gorensek, WD Carey, JA Washington, et al. (1993) Selective bowel decontamination with quinolones and nystatin reduces gramnegative and fungal infections in orthotopic liver transplant recipients. Clev Clin J Med 60 139-144.